117
Participants
Start Date
January 6, 2014
Primary Completion Date
February 5, 2018
Study Completion Date
December 3, 2020
Tepotinib 300 mg
Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Tepotinib 500 mg
Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Tepotinib 1000 mg
Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
Tepotinib
Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Sorafenib
Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
National Taiwan University Hospital, Taipei
Chang Gung Memorial Hospital, Linkou, Taoyuan District
National Cheng Kung University Hospital, Tainan City
Chi Mei Medical Center, Liou Ying, Tainan City
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
National Cancer Center, Goyang-si
Mackay Memorial Hospital, Taipei
Taipei Veterans General Hospital, Taipei
CHA Bundang Medical Center, CHA University, Seongnam-si
Seoul National University Bundang Hospital, Seongnam-si
Taichung Veterans General Hospital, Taichung
Keimyung University Dongsan Hospital, Daegu
Changhua Christian Hospital, Changhua
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
Beijing Friendship Hospital, Capital Medical University, Beijing
307 Hosptial of PLA, Beijing
Peking University Cancer Hospital, Beijing
Seoul National University Hospital, Seoul
Jilin Cancer Hospital, Changchun
Harbin Medical University Cancer Hospital, Harbin
Shanghai Cancer Hospital, Fudan University, Shanghai
Zhongshan Hospital Fudan University, Shanghai
Nanjing Bayi Hospital, Nanjing
Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing
Cancer Hospital, Tianjin Medical University, Tianjin
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Zhejiang
Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA, Fuzhou
The Third Xiangya Hospital of Central South University, Changsha
Sun Yat-sen University, Cancer Center, Guangzhou
Nanfang Hospital, Guangzhou
Dong-A University Hospital, Busan
Pusan National University Hospital, Busan
Kyungpook National University Hospital, Daegu
Kyung Hee University Hospital, Seoul
Korea University Anam Hospital, Seoul
Severance Hospital, Yonsei University, Seoul
Asan Medical Center, Seoul
Gangnam Severance Hospital, Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul
Korea University Guro Hospital, Seoul
Ajou University Hospital, Suwon
Pusan National University Yangsan Hospital, Yangsan
Merck KGaA, Darmstadt, Germany
INDUSTRY